The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
Bristol Myers Squibb (BMS) has agreed to acquire Forbius, a Montréal-based clinical-stage biopharmaceutical company developing biotherapeutics for treating cancer and fibrotic diseases. Financial terms were not disclosed.
Forbius has developed a...
The latest on manufacturing and potential treatments for COVID-19 with news from J&J, Novavax, Roche, Regeneron, BI, Dr. Reddy’s, CSL, and others.
J&J in Supply Pact with UK Gov’t for its COVID Vaccine Candidate Janssen Pharmaceutica NV,...
A roundup of news from Denmark (Novo Nordisk), Germany (Evotec, Novo Nordisk), Japan (Takeda), and the US (Lupin, Sun Pharma, Alnylam, Teva, and others).
Denmark
Novo Nordisk To Invest $135 M in Danish Production FacilitiesNovo Nordisk plans to...
Gilead Sciences has been issued a Complete Response Letter (CRL) by the US Food and Drug Administration (FDA) for its new drug application (NDA) for filgotinib, an investigational drug for treating moderately to severely active rheumatoid...
Sanofi has agreed to acquire Principia Biopharma, a South San Francisco, California-based clinical-stage biopharmaceutical company focused on immune-mediated diseases, for $3.68 billion.
Principia Biopharma is developing Bruton’s tyrosine kinase...
Mylan has launched a generic version of Biogen's Tecfidera (dimethyl fumarate), a drug for treating relapsing multiple sclerosis (MS). Tecfidera is Biogen’s top-selling drug with 2019 global sales of $4.4 billion.
Mylan is launching dimethyl...
Eli Lilly and Company and Innovent Biologics, a Suzhou, China-based biopharmaceutical company, have announced a global expansion of their strategic alliance for TYVYT (sintilimab), an anti-PD-1 monoclonal antibody immuno-oncology medicine, in a...
Johnson & Johnson (J&J) has agreed to acquire Momenta Pharmaceuticals, a Cambridge, Massachusetts-based company developing biosimilars and new biologics for rare immune-mediated diseases, for $6.5 billion.
Momenta’s lead asset is...
Gilead Sciences and Tango Therapeutics, a Cambridge, Massachusetts-based company developing cancer therapies, have expanded their strategic collaboration to discover, develop, and commercialize targeted immune-evasion therapies for cancer in a deal...
Bristol Myers Squibb (BMS) and Dragonfly Therapeutics, a Waltham, Massachusetts-based company specializing in cancer immunotherapies, have formed a collaboration, worth up to $475 million, for Dragonfly’s immunotherapy candidate, DF6002, for...
AstraZeneca has concluded an agreement with the European Commission (EC) to supply up to 400 million doses of AZD1222, the COVID-19 vaccine co-invented by the University of Oxford and its spinout company, Vaccitech, and licensed by...
Thermo Fisher Scientific reports that its $12-billion-plus offer to Qiagen, a provider of molecular diagnostics and sample preparation technologies, has lapsed after failing to acquire the needed number of shares to effectuate the...
The latest on manufacturing and potential treatments for COVID-19 with news from Pfizer, Gilead Sciences, AstraZeneca, Takeda, Novavax, Daiichi Sankyo, and others.
Pfizer in Pact to Manufacture Gilead’s Remdesivir for COVID-19Pfizer has entered...
Eisai's US subsidiary, Eisai Inc., has announced plans to re-locate its US headquarters in Woodcliff Lake, New Jersey to the former Roche headquarters campus in Nutley, New Jersey. The move is expected to be completed in late 2021 and will transfer...
Moderna, a clinical-stage biopharmaceutical company developing messenger RNA (mRNA) therapeutics and vaccines, has been awarded up to $1.525 billion, including incentive payments, by the US government to manufacture and deliver 100 million doses of...
